La Jolla Pharmaceutical Company
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$6.4M
Doctors Paid
8,547
Transactions
18,917
2024 Total
$705,902
Payment Breakdown by Category
Research$2.5M (38.6%)
Food & Beverage$730,569 (11.4%)
Consulting$247,937 (3.9%)
Travel$189,516 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.5M | 350 | 38.6% |
| Honoraria | $1.5M | 559 | 23.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 352 | 18.0% |
| Food and Beverage | $730,569 | 16,591 | 11.4% |
| Consulting Fee | $247,937 | 106 | 3.9% |
| Travel and Lodging | $189,516 | 677 | 3.0% |
| Space rental or facility fees (teaching hospital only) | $81,980 | 69 | 1.3% |
| Education | $33,362 | 211 | 0.5% |
| Grant | $20,000 | 2 | 0.3% |
Payments by Type
General
$3.9M
18,567 transactions
Research
$2.5M
350 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A PHASE 2, MULTI-CENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-BLIND STUDY WITH LJPC-401 FOR THE TREATMENT OF IRON OVERLOAD IN ADULT PATIENTS WITH HEREDITARY HEMOCHROMATOSIS | $1.3M | 0 | 267 |
| A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia | $419,361 | 0 | 4 |
| A MULTI-CENTER, RANDOMIZED, OPEN-LABEL, PARALLEL GROUP STUDY WITH LJPC-401 FOR THE TREATMENT OF MYOCARDIAL IRON OVERLOAD IN ADULT PATIENTS WITH TRANSFUSION-DEPENDENT BETA THALASSEMIA | $147,341 | 0 | 25 |
| A National Surveillance Program to Evaluate the In Vitro Potency of Standard-of-Care Antibiotics against Contemporary Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients | $129,100 | 0 | 4 |
| A STUDY OF LJPC-501 IN PEDIATRIC PATIENTS WITH HYPOTENSION | $102,103 | 0 | 10 |
| Angiotensin-II in Sepsis: Immune scRNA Seq Proposal Summary | $99,000 | 0 | 1 |
| EXPANDED ACCESS FOR LJPC-501 | $55,592 | 0 | 16 |
| Ex vivo modeling and simulation to guide Sulbactum Durlobactam dosing | $39,875 | 0 | 2 |
| Development and validation for the measurement of sulbactam and durlobactam in plasma free filtrate (PFF), effluent, and plasma via LC-MS/MS | $30,000 | 0 | 1 |
| Y site compatibility with sulbactam-durlobactam | $25,884 | 0 | 1 |
| Physical Compatibility with Sulbactam Durlobactam | $25,883 | 0 | 1 |
| In vitro static time kills with cefepime | $23,518 | 0 | 2 |
| EFFECT OF CARDIOPULMONARY BYPASS ON SERUM BIOMARKERS OF IRON | $16,296 | 0 | 7 |
| Angiotensin II as a first-line vasopressor for distributive shock for heart transplant and left ventricular assist device implantation recipients: A Pilot Study | $13,257 | 0 | 1 |
| The Effect of Angiotensin II on Vasoplegic Shock | $12,617 | 0 | 1 |
| Medication Use Evaluation with GIAPREZA for Patients with distributive shock including COVID-19 | $9,996 | 0 | 4 |
| Angiotensin II in Liver Transplantation (ANGLT-1): A Pilot Randomized Controlled Trial | $7,116 | 0 | 1 |
| DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) pilot: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock, a randomized controlled pilot trial | $1,920 | 0 | 1 |
| A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis | $909.70 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Peter Murphy, M.d, M.D | Critical Care Medicine | Carmichael, CA | $28,599 | $0 |
| Dr. Kameron Ferdowsali, M.d, M.D | Internal Medicine | Vancouver, WA | $23,112 | $0 |
| Dr. Aaron Strumwasser, Md, MD | Surgical Critical Care | Lynwood, CA | $22,466 | $0 |
| Guillermo Padilla, M.d, M.D | Infectious Disease | Shreveport, LA | $22,426 | $0 |
| Dr. Adam Evans, Md, MD | Internal Medicine | Orlando, FL | $21,926 | $0 |
| Dr. Charles Hong, Md Phd, MD PHD | Cardiovascular Disease | East Lansing, MI | $21,000 | $0 |
| Christopher Cooper, Md, MD | Infectious Disease | Altamonte Springs, FL | $19,547 | $0 |
| Bruce Abell, Md, MD | Surgery | Washington, DC | $19,140 | $0 |
| Unknown Provider | — | — | $18,760 | $0 |
| Mr. Per Rosenkvist, Acnp-Bc, ACNP-BC | Critical Care Medicine | Livingston, NJ | $18,607 | $0 |
| Michael Mccurdy, Md, MD | Critical Care Medicine | Towson, MD | $17,908 | $0 |
| Dr. Miguel Sierra-Hoffman, M.d, M.D | Infectious Disease | Victoria, TX | $17,248 | $0 |
| Mr. Daniel Feinstein, M.d, M.D | Critical Care Medicine | Pinehurst, NC | $16,933 | $0 |
| Jason Sniffen, Do, DO | Infectious Disease | Altamonte Springs, FL | $16,222 | $0 |
| Dr. Arthur Jeng, M.d, M.D | Infectious Disease | Sylmar, CA | $15,239 | $0 |
| Dr. Craig Ainsworth, Md, MD | Critical Care Medicine | Fort Sam Houston, TX | $14,964 | $0 |
| Charles Rose | Infectious Disease | Lexington, KY | $14,766 | $0 |
| Firas Koura, M.d, M.D | Pulmonary Disease | Georgetown, KY | $13,545 | $0 |
| Fares Khater, Md, MD | Internal Medicine | Whitesburg, KY | $13,520 | $0 |
| Jacob Delarosa, Md, MD | Cardiovascular Disease | Pocatello, ID | $13,330 | $0 |
| William Mcgee, Md, MD | Critical Care Medicine | Springfield, MA | $12,227 | $0 |
| Dr. Joseph Gathe, M.d, M.D | Infectious Disease | Houston, TX | $12,200 | $0 |
| Dr. Edward Dominguez, M.d, M.D | Infectious Disease | Dallas, TX | $11,553 | $0 |
| Markian Bochan, Md, MD | Infectious Disease | Carmel, IN | $11,411 | $0 |
| Dr. Bryan Kraft, Md, MD | Pulmonary Disease | Saint Louis, MO | $11,111 | $0 |
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company has made $6.4M in payments to 8,547 healthcare providers, recorded across 18,917 transactions in the CMS Open Payments database. In 2024, the company paid $705,902. The top product by payment volume is GIAPREZA ($3.9M).
Payments were distributed across 138 medical specialties. The top specialty by payment amount is Critical Care Medicine ($900,051 to 661 doctors).
Payment categories include: Food & Beverage ($730,569), Consulting ($247,937), Research ($2.5M), Travel & Lodging ($189,516).
La Jolla Pharmaceutical Company is associated with 3 products in the CMS Open Payments database.